CURE Pharmaceutical Holdings Stock Symbol: (OTC:
CURR), a holding company focused on the innovation of pharmaceutical
technology, wellness products and drug delivery, announced today that it has
issued a letter to its shareholders providing commentary on the Company’s
recent announcements and upcoming plans.
Highlights of the letter include:
Ø CURR’s efforts to
further position itself as an integrated healthcare company with its recent
acquisition of The Sera Labs, a high-margin, multi-channel marketing and branding
company with accelerating sales of its more than 20 products in the health
& wellness, beauty, and pets categories and strong traction in both
e-commerce and wholesale-to-retail distribution with total retail doors
exceeding 8,850 in the U.S. to date
o
CURE acquired 100 percent of
privately held The Sera Labs for $20 million, which consists primarily of stock
with key earn out considerations totaling up to an additional $20 million
within two years of completing the acquisition.Founder and CEO Nancy Duitch,
who is well-known for her track record for launching some of the
largest-selling products on the market, will help the Company generate revenue
on its existing technologies in a wellness vertical, without the need for
partners and further strengthen the already sales-generating SeraLabs® brand.
Ø The Sera Labs
newest consumer product that uses CURE’s patented and advanced oral thin film
strip technology under the trademark name Nutri-Strips with RAD3 (Rapid
Activation Delivery) to deliver novel vitamins and supplements to consumers
across the nation.
o
Formulations include a sleep aid called Sleep A.S.A.P.™, EnergY™
designed to enhance performance and mental focus, an electrolyte and muscle
recovery product called RecoverB™, and immunD™ for immune support.
Ø CURR earning NSF
International, cGMP certification for its 25,000 square foot manufacturing
facility
o
This certification enables manufacturers to become independently
certified by NSF as complying with cGMP requirements as listed in Section 8 of
NSF/ANSI Standard 173. This certification positions CURE’s manufacturing
capabilities at the forefront of quality standards set by the various
regulatory agencies.
Ø The Company’s
recent pharmacokinetic (PK) study on its 25mg cannabidiol (CBD) oral thin film
(OTF) showing improved bioavailability of cannabidiol in healthy subjects
o
In 14 healthy adults, those who used the OTF experienced a
significantly higher serum concentration (Cmax) and significantly faster
absorption (Tmax) than those who consumed a commercially available CBD soft
gel. The study also suggests that the CUREform™ delivery platform, which entails
solubilization and encapsulation of the molecule, might deliver better results
than solubilization alone, as used in the soft gel product, and may play a
synergistic or additive role in bioavailability.
CURR CEO Rob Davidson commented, "2020 has not been without its
challenges for any industry; however, CURE is still well-positioned to become a
fully-integrated health and wellness company, as propelled by the acquisition
of SeraLabs. We continue to forge ahead in our pharmaceutical research using
our proven drug delivery platforms and adapt to service the burgeoning
nutraceutical market. We’ve focused on improving our manufacturing capabilities
and proved yet again the superiority of our drug delivery technology. All in
all, I am more confident than ever in CURE’s ability to capitalize on our
vision of delivering the promise of healthier lives."
About SeraLabs
SeraLabs® is a trusted leader in the health, wellness, and
beauty sectors of innovative products with cutting edge technology and superior
ingredients such as CBD. SeraLabs® creates high quality products that use
science-backed, proprietary formulations. Its more than 20 products are sold
under the brand names SeraRelief™, SeraTopical™, SeraLabs™, Gordon’s Herbals™
and SeraPets™. SeraLabs® sells its products at affordable prices, making them
easily accessible on a global scale. Strategically positioned in the growth
market categories of beauty, health & wellness, and pet care, SeraLabs®
products are sold in major national drug, grocery chains and mass retailers.
The company also sells products under private label to major retailers and
multi-level marketers, as well as direct-to-consumer (DTC), via online website
orders, including opt-in subscriptions. For more information visit: www.SeraLabsHealth.com and
follow @theseralabs
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a
patented drug delivery platform that offers a number of unique immediate- and
controlled-release drug delivery vehicles designed to improve drug efficacy,
safety, and patient experience for a wide range of active ingredients.
As a vertically
integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and
cGMP-certified manufacturing facility enables it to partner with pharmaceutical
and wellness companies worldwide for private and white-labeled production. CURE
has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets
in Europe.
For more info
on Stock Symbol: CURR visit: https://www.curepharmaceutical.com/
###
